Hair Repigmentation Associated with the Use of Lenalidomide: Graying May Not Be an Irreversible Process

This article reviews eyelash elongation as a side effect of EGFR inhibitors in cancer treatment, finding that the condition is typically not severe and may be managed by trimming.

This study suggests that topical T3 can induce hair follicles to enter the growth phase and may reverse graying in mice, with in vitro results supporting enhanced hair shaft growth.

This review discusses the classification, pathogenesis, and management of skin, hair, nail, and mucosal changes due to EGFR inhibitors, emphasizing the importance of informing patients to improve therapy compliance.

In this case report, the authors suggest that topiramate, used for treating bipolar disorder, may cause trichomegaly, or excessive eyelash growth, in patients.

This study found that continuous expression of epidermal growth factor in transgenic mice prevented hair follicles from entering the catagen phase, implicating EGF as a crucial regulator in hair cycle progression.

This article discusses the biologic and psychosocial significance of hair, the current limitations in hair growth drugs, and anticipates future therapies based on advancing hair follicle research.

In this study, different types of catagen in the C57BL/6 mouse model exhibited varying effects on hair follicle melanocytes and melanin distribution, with spontaneous and dexamethasone-induced catagen showing pigment incontinence, while cyclophosphamide-induced catagen retained dendritic melanocytes but increased ectopic melanin.

Hair color production is closely linked to the active growth phase of hair in mice and may also influence hair growth itself.